08:00 , Nov 9, 2009 |  BioCentury  |  Finance

Ebb & Flow

Biovitrum AB (SSE:BVT) is doing some fancy financial footwork to pull together the SEK3.5 billion ($496.7 million) it needs to pay for the acquisition of Swedish Orphan International AB , a combination the companies expect...
23:55 , Nov 3, 2009 |  BC Extra  |  Financial News

On-Q-ity raises $21 million

On-Q-ity Inc. (Waltham, Mass.) raised $21 million in a series A round led by Mohr Davidow Ventures (MDV). Bessemer Venture Partners; Physic Ventures; and Northgate Capital also participated. On-Q-ity is developing diagnostics using its circulating...
07:00 , May 19, 2008 |  BioCentury  |  Finance

Ebb & Flow Focus

The American Society of Clinical Oncology meeting is on the horizon, with the first spate of corporate press releases pouring forth last week to coincide with posting of abstracts for the May 30-June 2 conference...
07:00 , Sep 3, 2007 |  BioCentury  |  Strategy

Back to School: Innovation & leadership

Over the past two years, Back to School has been exploring the relationship between innovation and the economic returns from drug development and the creation of patient value. These discussions have argued that as pricing...
07:00 , Apr 30, 2007 |  BioCentury  |  Strategy

MedImmune chronicles

MedImmune chronicles Since late 2000, MedImmune's stock performance has lagged its peers, as gauged by a price-weighted index consisting of Amgen (AMGN), Biogen Idec (BIIB), Genentech (DNA), Genzyme (GENZ) and Gilead (GILD). In fact, prior...
07:00 , Apr 9, 2007 |  BioCentury  |  Strategy

Antibody takeouts

Antibody takeouts Company Acquirer Value Status (A) Abgenix Amgen $2,200 Ph III Cambridge Antibody (B) AstraZeneca $1,300 Mkt Domantis GlaxoSmithKline $455 Preclin Morphotek Eisai $325 Ph I/II Cellective MedImmune $160 Preclin Abmaxis Merck $80 NA...
08:00 , Jan 22, 2007 |  BioCentury  |  Strategy

Offshore shopping

In the past, most Western companies that went to Japan were looking for local big pharma companies to develop and market their compounds in Japan. In recent years, more companies have reversed the paradigm and...
07:00 , May 8, 2006 |  BC Week In Review  |  Company News

Merrimack management update

Merrimack Pharmaceuticals Inc. , Cambridge, Mass.   Business: Autoimmune, Proteomics   Hired: Fazal Khan as VP of manufacturing, formerly VP at Cellective Therapeutics Inc.  ...
03:14 , Feb 3, 2006 |  BC Extra  |  Financial News

MedImmune reports earnings

MEDI reported fourth quarter diluted adjusted EPS of $0.08, beating the Street estimate by $0.03 but off 62% from $0.21 in the prior year's quarter. The decline was driven in part by increases in SG&A...
08:00 , Jan 9, 2006 |  BioCentury  |  Finance

Ebb & Flow

Pacific Growth Equities last week unveiled plans to avoid what it thinks is the increasing commoditization of sellside research. The firm rolled out its Sector Sales department to provide unpublished investment ideas to the firm's...